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Background and Objective. Aim of the study was to
assess the efficacy of VEMB, a short-lasting thera-
peutic regimen (50 days) which alternates two
myelotoxic drugs (cyclophosphamide and mitox-
antrone) every week with two less hematologically
toxic drugs (vincristine and bleomycin) in the treat-
ment of aggressive NHL in the elderly (over 70).
Design and Methods. Between November 1994 and
March 1996, 37 patients aged more than 70 years,
with highly or moderately malignant NHL (according
to the Working Formulation) have been enrolled into
the study. The stage of the disease ranged between
II and IV according to Ann Arbor. Mean age was 77
years; 14 patients (38%) had stage IV; 19 patients
(51%) had LDH higher than normal; 26 patients (70%)
had extranodal and 9 patients (24%) had bulky dis-
ease at time of diagnosis.
Results. Sixty-two percent of patients achieved a
complete and 22% a partial remission. Non-respon-
ders amounted to 5%. Four patients (11%) died dur-
ing the therapy. Nine patients (24%) experienced
grade III-IV neutropenia. The most frequently
observed event was mild neurotoxicity (43% of cas-
es). The overall survival rate at 30 months was 55%.
DFS at 24 months was 66%.
Interpretation and Conclusions. VEMB is a therapeu-
tic regimen whose efficacy is comparable to that of
the other derived MACOP-B therapeutic regimens
used in the elderly NHL. It has proved to have a good
feasibility, though the number of toxic deaths should
not be neglected.
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Since the introduction of anthracycline-contain-ing regimens the prognosis of highly or moder-ately malignant non-Hodgkin lymphomas has
markedly improved, with about 50% of patients pro-
jected to be cured.1
However, these encouraging results have been
obtained mostly in patients aged less than 65 years
of age at time of diagnosis. In the past older patients
have been usually excluded by aggressive treatments
considered extremely toxic. In fact, regardless the
increasing incidence of NHL in the elderly (up to 40%
of aggressive NHL occur in patients aged more than
65 years), only a small number of highly selected
patients have been treated with the best available
therapies and at full planned doses.2,3
In addition, different recent studies have shown
that in patients with NHL age should be regarded as
an unfavorable prognostic factor.4,5
Over the last few years some specific protocols have
been designed for elderly patients; in particular, the
Vancouver group designed a weekly administration of
cytostatic drugs: LD-ACOP-B,6 VABE6 and P/DOCE.7
P-VEBEC,8 P-VABEC9 and VNCOP-B10 have also been
designed according to the same model. On the other
hand VMP,11 developed by the Aviano group, prefers
the oral administration of chemotherapeutic drugs.
Essentially, such regimens aim at reducing toxicity in
patients who, because of age and the frequently con-
current diseases, show less tolerance for the treatment.
In 1994, our cooperative group (Gruppo Italiano per
lo Studio dei Linfomi [GISL]) designed a new protocol,
called VEMB, which alternates two myelotoxic drugs
(mitoxantrone and cyclophosphamide) with two
drugs having low bone-marrow toxicity (vincristine
and bleomycin). The aim is to deliver a satisfactory
drug amount, while at the same time allow for a bet-
ter recovery in subjects with reduced bone-marrow
reserves. Mitoxantrone was chosen as an alternative
to doxorubicin because of the reported lower inci-
dence of cardiotoxicity.12
Materials and Methods
Between November 1994 and March 1996, 37
patients with newly-diagnosed NHL of high or inter-
mediate grade according to the Working Formula-
tion,13 were enrolled in the study by 10 different Ital-
ian onco-hematological centers. None of patients
had undergone previous treatments.
The eligibility criteria were as follows:
• age above 70 years;
• histological diagnosis of aggressive NHL (D to H
categories according to the Working Formula-
tion);
• Ann Arbor14 stage II to IV;
• performance status 0 to 3 (according to ECOG);
• normal liver, heart, renal and respiratory func-
tions;
• HIV negativity.
The diagnostic procedures to get access to the study
included the histological diagnosis and the standard
staging investigations, which were as follows:
• physical examination;
• complete hematological and biochemical screen-
ing;
• chest and abdominal CT-scan;
• bone-marrow biopsy;
Additional instrumental examinations were carried
out only if clinical indications were specified.
Therapeutic regimen
VEMB was administered as follows:
• cyclophosphamide 350 mg/m2 i.v. and mitox-
antrone 10 mg/m2 i.v. at days 1, 15, 29, 43.
• vincristine 1.4 mg/m2 i.v. (maximum dose 2 mg)
and bleomycin 5 mg/m2 i.v. at days 8, 22, 36, 50;
• oral prednisone 50 mg at days 1-15, then 50 mg
at alternating days.
No dose reduction was specified based on myelo-
toxicity. Regular administration of vincristine 1 mg was
recommended in case of neurotoxicity > grade 1.
The use of growth factors was allowed though not
specified.
Response
The re-staging investigations at the end of therapy
included a reassessment of the sites involved at the
onset of the disease and, in all cases, a chest and
abdominal CT-scan.
Complete remission (CR) meant complete disap-
pearance of the clinical and radiological signs of the
disease for at least four weeks after the end of thera-
py. Partial remission (PR) meant the disappearance
of at least 50% of the measurable lesions. Patients
with a response of less than 50% were classified as
non-responders (NR). Recurrences were defined as
the presence of NHL in patients who had been in
complete remission for at least four weeks.
Survival was measured from the time of diagnosis
to the last observation. DFS for patients in complete
remission was calculated from the time of the last
therapy to the date of the last observation or of the
relapse. The OS and DFS curves were drawn accord-
ing to Kaplan and Meyer’s method.15
Dose intensity
The dose intensity (DI) analysis was performed
according to the method proposed by Hryniuk and
Bush.16 For patients completing the planned 8 cours-
es of chemotherapy, the DI of each drug was con-
sidered together with the amount of each drug, nor-
malized to the body surface area, administered dur-
ing the first 50 days, 50 days was the time required
to complete the therapy. 
For patients who received less than 8 courses of
chemotherapy because of early death or disease pro-
gression, DI was expressed as the ratio of the actual-
ly delivered dose to the dose prescribed in the regi-
men over the same time frame. Vincristine was
excluded from the calculation of DI, since a dose
reduction was specified by the protocol in case of
neurotoxicity, even of grade I.
Results
Table 1 summarizes the main characteristics of the
37 enrolled patients.
The mean age was 77 years (range 70-86); 19
patients (51%) had LDH above upper normal limit
and 14 (38%) were in stage IV. Extranodal localiza-
tion was quite frequent: it was found in 26 patients
(70%); 9 patients (25%) had a bulky disease.
Table 2 summarizes therapeutic results. Twenty-
three patients (62%) had complete remission and 8
(22%) partial remission, with an overall response rate
of 84%. The role of radiation therapy was neglectable
since it was used in one case only (to consolidate a
CR which had been already obtained with VEMB).
Six failures were observed: 4 early deaths due to
therapy-related toxicity and 2 cases with less than par-
tial response. Three patients died during induction
therapy for fatal infections (septic shock, 1; pul-
monary infection, 2): all these patients had multiple
negative prognostic factors at diagnosis; none  of
them had a significant neutropenia when the infection
occurred. One patient (with gastric localization) died
from gastric hemorrhage. The 2 patients who failed to
obtain a major response died for disease progression
4 and 8 months after diagnosis, respectively.
Out of the 8 patients with PR, one achieved CR
with salvage therapy.
After a median follow-up of 17 months, OS at 30
months was equal to 55% (Figure 1). Actuarial DFS at
24 months was 66% with 16/23 patients in CCR (Fig-
ure 2). Six out of 7 patients who relapsed had a recur-
rence within the first year from the end of treatment.
Finally, 2 patients died for reasons unrelated to
lymphoma (stroke, 1; acute heart failure, 1) at the
age of 82 and 80 respectively. 
Toxicity and dose intensity
The side effects, assessed according to the WHO
scale, are summarized in Table 3. VEMB was gener-
ally well tolerated. The most frequent side effect (43%
of cases) was mild neurotoxicity (mainly in the form
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of constipation), but no severe neurotoxicity has been
observed. Severe toxicity was found with significant
frequency only at the hemopoietic level (neutropenia
stage 3-4 in 24% of cases). However, it did not pre-
vent 16 patients (43%) from completing therapy
within the 50 expected days, so that the mean treat-
ment completion time was 58 days (range 50-85).
The data to calculate DI were available for 36
patients. They received 98%, 97% and 100% of the
planned dose of cyclophosphamide, mitoxantrone
and bleomycin, respectively. In most cases it was pre-
ferred to postpone treatment rather than reducing
drug dosage. Considering both the administered
drug dosage and the time required to complete ther-
apy as planned, the actual delivered DI was 90% for
the whole group.
Prognostic factors
Table 4 summarizes the analysis of the main prog-
nostic factors with respect to response and survival.
VEMB treatment in aggressive NHL
Table 1. Clinical features at diagnosis of the 37 patients
studied.
Characteristics No. %
Median age:  77 years (range 70-86)
Sex
Male 20 54
Female 17 46
Stage
II 14 38
III 9 24
IV 14 38
Histology
D 1 3
E 1 3
F 14 38
G 14 38
H 7 18
Extranodal disease
Yes 26 70
No 11 30
Bulky
Yes 9 24
No 28 76
LDH
Normal 18 49
Elevated 19 51
Performance status (ECOG)
0-1 26 70
2-3 11 30
Table 2. Response.
Type of response No. %
CR 23 62
PR 8 22
NR* 6 16
*Including 4 patients died during induction therapy due to toxicity.
Table 3. Hematological and clinical toxicity.
Side effect WHO (1-2) WHO (3-4)
Anemia 1 (3%) 1 (3%)
Neutropenia 15 (41%) 9 (24%)
Infections 5 (14%) 4(11%)*
Mucositis 6 (16%) 1 (3%)
Neurotoxicity 16 (43%) 0 (0%)
*including 3 patients died during induction.
OVERALL SURVIVAL
0
10
20
30
40
50
60
70
80
90
100
0 4 8 12 16 20 24 28 32 36
MONTHS
%
Figure 1. Overall survival of 37 patients treated with VEMB.
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Figure 2. Disease-free survival of 23 CRs treated with
VEMB.
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The prognostic factors positively affecting CR result-
ed the stage of the disease (p = 0.002) and the
absence of bone marrow involvement (p = 0.01).
Concerning the overall survival rate, the only signifi-
cantly positive factor was the female gender (p =
0.003), with good balance between the main prog-
nostic factors and gender.
Discussion
Most studies4,17,18 agree on the fact that elderly
patients with aggressive NHL have a worse prognosis
than younger patients with the same conditions. This
would depend on the higher incidence of concurrent
diseases and on the resulting inability of adopting an
aggressive therapeutic regimen or completing it with-
in the required timing or in an adequate dosage.
In the past, since CHOP was regarded as the gold
standard in the therapy of aggressive NHL, attempts
were made at adapting this therapeutic regimen to
the elderly population with an aim at reducing its tox-
ic effects as much as possible.19,20
Other groups21,22 preferred to use CHOP at full dos-
es based on the assumption that inadequate treat-
ment of chemoresponsive neoplasias is worse than
chemotherapy-induced toxicity. 
Since the early 90’s, attempts have been made at
using chemotherapeutic regimens specially designed
for the elderly, giving priority to one or more of the fol-
lowing guidelines: 1) greater use of the oral cytotoxic
therapy, such as VMP11 and PEN;23 2) use of less tox-
ic drugs, similar to those already used (e.g. mitox-
antrone to reduce cardiotoxicity);24 and 3) short-last-
ing therapy.25
With an aim to treat the elderly patients with short-
er therapeutic courses, several MACOP-B-derived reg-
imens have been used. Initially the Vancouver group
kept to the 12 original weeks (LD-ACOP-B and
VABE)6 which were then reduced to 8 (P/DOCE).7
Similar regimens were used by other groups (P-
VEBEC,8 P-VABEC9 and VNCOP-B10). All required 8
weeks of treatment.
Also VEMB, whose results are described in this
report, should be included in this last group of regi-
mens: the CR rate (62%), the OS (55% at 30 months)
and DFS (66% at 24 months) are comparable to the
results obtained with other regimens of the same
type. These results seem to be significant in light of
the fact that the mean age (77 years) of the patients
enrolled in our group is the highest of all published
studies.
The recorded toxicity should also be taken into
consideration, especially because of the quite high
number of toxic deaths (11%) which is comparable
to the mortality rate  found with CHOP.24 Among
the side-effects, the most frequent one (43%) was
neurotoxicity-induced constipation, most likely relat-
ed to the frequent administration of vincristine.
Myelotoxicity was also acceptable (neutropenia stage
3-4 in 24% of cases), considering that the use of
growth factors was not planned.
The satisfactory actual DI for the whole group has
confirmed that the VEMB regimen is quite feasible.
The relatively low number of patients enrolled in
the study does not allow to draw any final conclu-
sions for the statistical analysis of prognostic factors;
in such a view, one should probably also consider the
significantly favorable prognosis for female patients.
In agreement with other studies,8,17,26 however, one
should also point to the negative role of bone mar-
row localization and of the advanced stage of the dis-
ease in influencing the possibility of reaching the CR.
In conclusion, even if the case series do not overlap
in terms of age and number of enrolled patients, the
results obtained with VEMB are comparable to those
of the other therapeutic MACOP-B-derived regimens
and can be favorably compared with the previously
described regimens, especially CHOP. On the basis
of the described results, a randomized prospective
study on a MACOP-B-derived regimen and CHOP
seems to be desirable. Such study should, apart from
the clinical results, also consider the quality of life
before, during and after therapy since this seems to be
particularly important in patients with limited life
expectancy. Furthermore, even if not using complex
procedures which are difficult to implement, one
should carry out, as accurately as possible, an assess-
ment of the concurrent diseases since they are factors
which may affect the good feasibility of a chemother-
apeutic regimen in the elderly.27
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Table 4. Prognostic factors.
Response OS
Stage (II-III vs IV) p = 0.002 NS
Age (< 75 vs >75) NS NS
Sex (F vs M) NS p = 0.003
Symptoms (A vs B) NS NS
Bone marrow (NEG vs POS) p = 0.01 NS
LDH (NORM vs HIGH) NS NS
Bulky (NEG vs POS) NS NS
Performance status (ECOG 0-1 vs 2-3) NS NS
Dose intensity (> 0.9 vs < 0.9) NS NS
OS: overall survival.
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